Gain Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
-3.4%projected annual EPS growth
Analyst Coverage
5analysts covering
FY EPS (est.)
-$0.60next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Phase 1b Clinical Trial Final Results Readout | 31 Oct 2026 |
Monitoring Framework
Key Performance Indicators
Cerebrospinal Fluid (CSF) Glucosylsphingosine (GluSph) Reduction Quarterly81.0Target: Sustained reduction back toward healthy baseline levels
MDS-UPDRS Part II and Part III Score Stability Quarterly150.0Target: Long-term motor and functional stability (durability beyond 12 months)
Cash Runway (Months of Operations) Quarterly900.0%Target: Extend runway beyond Q100 2027 via strategic financing or partnerships%
Watch Items
- FDA Investigational New Drug (IND) Clearance for Phase 2 TrialTrigger: Official FDA clearance of the IND applicationAction: Initiate the Phase 2 clinical trial of GT-02287 in Parkinson's disease
- Phase 1b Clinical Trial Nine-Month Extension CompletionTrigger: Completion of the extension study (expected Q3/Q4 2026)Action: Analyze and present final safety, tolerability, and long-term biomarker data
- Going Concern Risk and Capital DilutionTrigger: Cash reserves falling below $10 million without secured fundingAction: Execute strategic equity financing (e.g., projected $60M raise) or secure a development partner
Research as of 20 Jun 2026